Iradimed (IRMD) Current Deferred Revenue (2013 - 2026)

Iradimed (IRMD) has reported Current Deferred Revenue for 14 consecutive years, with $7.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Deferred Revenue rose 14.31% year-over-year to $7.5 million in Q2 2026; TTM through Jun 2026 was $7.5 million, a 14.31% increase from a year earlier, with the FY2025 full-year figure at $6.8 million, up 30.38% from the prior year.
• Current Deferred Revenue was $7.5 million for Q2 2026 at Iradimed, up from $7.2 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $7.5 million in Q2 2026 and troughed at $1.6 million in Q3 2022.
• A 5-year average of $3.8 million and a median of $2.6 million in 2022 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue tumbled 35.05% in 2022 and soared 159.68% in 2025, its largest moves.
• Over 5 years, Current Deferred Revenue stood at $3.4 million in 2022, then retreated by 23.8% to $2.6 million in 2023, then soared by 104.36% to $5.3 million in 2024, then jumped by 30.38% to $6.8 million in 2025, then gained by 9.97% to $7.5 million in 2026.
• The last three Current Deferred Revenue figures came in at $7.5 million (Q2 2026), $7.2 million (Q1 2026), and $6.8 million (Q4 2025), per Business Quant data.